CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Age-related macular degeneration (AMD) is a leading cause of central vision loss, with an increasing prevalence related to a growing economic burden. Understanding the epidemiological changes of AMD is essential for targeting the resource allocation of medicine, interventions, and the economy.

Material and methods:
The global prevalence and years lived with disability of AMD by sociodemographic index (SDI), sex, and age groups from 1990 to 2019 based on the Global Burden of Disease Study 2019 were retrieved and utilized to estimate epidemiological changes.

Results:
The global AMD population increased significantly from 3581.33 thousand in 1990 to 7792.53 thousand in 2019, and the years lived with disability significantly increased from 296.77 thousand years to 564.06 thousand years. The AMD burden was higher among females (57.77% to 59.20%), the elderly (65–74 years old), and individuals in high-middle and middle SDI regions from 1990 to 2019. The most significant increase in global burden occurred between 2014 and 2019. The age-standardized rate was predicted to remain stable, but the AMD case number was predicted to increase over the next 20 years. Tobacco use was the major diminishing risk factor.

Conclusions:
The present study demonstrated the increasing AMD burden in the past 30 years and predicted the increasing change of AMD prevalence in the next 20 years in the context of the aging global population. Disease burdens, including case number and age-standardized rate, were higher among females, the elderly, and individuals in high-middle and middle SDI regions. The present findings will contribute to healthcare investment and policymaking.

 
REFERENCES (31)
1.
Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet 2012; 379: 1728-38.
 
2.
Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration. Ophthalmology 2001; 108: 697-704.
 
3.
Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006; 124: 1754-60.
 
4.
Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. Nat Rev Dis Primers 2021; 7: 31.
 
5.
Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol 2017; 6: 493-7.
 
6.
Xu X, Wu J, Yu X, Tang Y, Tang X, Shentu X. Regional differences in the global burden of age-related macular degeneration. BMC Public Health 2020; 20: 410.
 
7.
Joachim N, Mitchell P, Burlutsky G, Kifley A, Wang JJ. The incidence and progression of age-related macular degeneration over 15 years: the Blue Mountains Eye Study. Ophthalmology 2015; 122: 2482-9.
 
8.
Marques AP, Ramke J, Cairns J, et al. Global economic productivity losses from vision impairment and blindness. EClinicalMedicine 2021; 35: 100852.
 
9.
Zhang T, Jiang W, Song X, Zhang D. The association between visual impairment and the risk of mortality: a meta-analysis of prospective studies. J Epidemiol Community Health 2016; 70: 836-42.
 
10.
van Nispen RM, Virgili G, Hoeben M, et al. Low vision rehabilitation for better quality of life in visually impaired adults. Cochrane Database Syst Rev 2020; 1: CD006543.
 
11.
Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1459-544.
 
12.
Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204-22.
 
13.
Qian J, Chen Y, Lu D, Ma J, Liu K. The prevalence, disability-adjusted life years, and mortality of hypertensive heart disease and its attributable risk factors: results from the Global Burden Disease Study 2019. Arch Med Sci 2023; 19: 1186-200.
 
14.
Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392:1789-858.
 
15.
Lin X, Lou L, Miao Q, et al. The pattern and gender disparity in global burden of age-related macular degeneration. Eur J Ophthalmol 2021; 31: 1161-70.
 
16.
Yang X, Chen H, Zhang T, et al. Global, regional, and national burden of blindness and vision loss due to common eye diseases along with its attributable risk factors from 1990 to 2019: a systematic analysis from the Global Burden of Disease Study 2019. Aging (Albany NY) 2021; 13: 19614-42.
 
17.
Reitsma MB, Kendrick PJ, Ababneh E, et al. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet 2021; 397: 2337-60.
 
18.
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health 2014; 2: e106-16.
 
19.
Zhang Y, Chen A, Zou M, et al. Disease burden of age-related macular degeneration in china from 1990 to 2019: findings from the Global Burden of Disease Study. J Glob Health 2021; 11: 08009.
 
20.
Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res 2018; 64: 1-55.
 
21.
Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004; 111: 1280-7.
 
22.
Seddon JM. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996; 276: 1141-6.
 
23.
Christen WG. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 1996; 276: 1147-51.
 
24.
Zelinger L, Martin TM, Advani J, et al. Ultra-rare complement factor 8 coding variants in families with age-related macular degeneration. iScience 2023; 26: 106417.
 
25.
Kubicka-Trzaska A, Zuber-Laskawiec K, Dziedzina S, Sanak M, Romanowska-Dixon B, Karska-Basta I. Genetic variants of complement factor H Y402h (Rs1061170), C2 R102g (Rs2230199), and C3 E318d (Rs9332739) and response to intravitreal anti-vegf treatment in patients with exudative age-related macular degeneration. Medicina (Kaunas) 2022; 58: 658.
 
26.
Mahendra CK, Tan LTH, Pusparajah P, et al. Detrimental effects of uvb on retinal pigment epithelial cells and its role in age-related macular degeneration. Oxid Med Cell Longev 2020; 2020: 1904178.
 
27.
Hsu MH, Hsu CA, Lai SC, Yen JC. Gout as a risk factor for age-related macular degeneration in Taiwanese adults-a population-based study in Taiwan. Int J Environ Res Public Health 2022; 19: 10142.
 
28.
Ganesh D, Chiang JN, Corradetti G, Zaitlen N, Halperin E, Sadda SR. Effect of statins on the age of onset of age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2023; 261: 2245-55.
 
29.
Lee H, Han KD, Shin J. Association between glycemic status and age-related macular degeneration: a nationwide population-based cohort study. Diabetes Metab 2023; 49: 101442.
 
30.
Jin K, Ye J. Artificial Intelligence and deep learning in ophthalmology: current status and future perspectives. Adv Ophthalmol Pract Res 2022; 2: 100078.
 
31.
Li S, Chen H, Man J, et al. Changing trends in the disease burden of esophageal cancer in China from 1990 to 2017 and its predicted level in 25 years. Cancer Med 2021; 10: 1889-99.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top